Dose-dependent efficacy and safety of centanafadine in patients with attention-deficit/hyperactivity disorder: A systematic review of the latest evidence

Centanafadine is a multimodal norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI) that has been evaluated for the treatment of attention-deficit/hyperactivity disorder (ADHD) across pediatric, adolescent, and adult populations. This systematic review aimed to evaluate the efficacy, safety, and tolerability of centanafadine compared with placebo, with particular emphasis on dose-response patterns across different age groups. PubMed/MEDLINE, Embase, Scopus, and the Cochrane Central…

via https://pubmed.ncbi.nlm.nih.gov/42877260/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1lqZ3NPYysePVKsoyz66mDSgu4veDGJwnUBS47TBQPoOuNZY5J&fc=None&ff=20261021011005&v=2.20.1